Biocept Inc(BIOC)stock report

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Market Cap:8.5M; Shares Outstanding:23.0M; Short Interest: 8.93%; Q3 2019(9/30/19): Cash 6.54M. Loss 5.69M

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -9.01 61.79% -9.08%
2019.3.31 -0.61 81.68% 93.23%
2019.6.30 -0.83 86.10% -36.07%
2019.9.30 -1.1 86.68% -32.53%


Date Sales % last year % last quarter
2018.12.31 3.25M -35.87% 35.98%
2019.3.31 1.02M 26.93% -68.62%
2019.6.30 2.22M 35.99% 117.65%
2019.9.30 3.74M 56.64% 68.47%


Insider Transactions:

Institution Ownership:

Total institutions: 18,no change
Shares hold: 371.7k shares. no change
shares% hold: 0.78%,no change

Analyst Ratings:

Leave a Reply